ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions
  • ACR Late-breaking Abstract Oral Session
  • ACR Late-breaking Abstracts Poster Session
  • ACR/ARHP Combined Epidemiology Abstract Session
  • ACR/ARHP Combined Rehabilitation Abstract Session
  • ACR/REF Edmond L. Dubois, MD Memorial Lectureship: Hydroxychloroquine Reduces Thrombosis in Systemic Lupus Erythematosus, Particularly in Antiphospholipid Positive Patients
  • Antiphospholipid Syndrome
  • B-cell Biology and Targets in Autoimmune Disease
  • Biology and Pathology of Bone and Joint
  • Biology and Pathology of Bone and Joint: Osteoarthritis
  • Biology and Pathology of Bone and Joint: Regulation of Bone Cells
  • Care of Patients With Rheumatoid Arthritis
  • Cell-cell Adhesion, Cell Trafficking and Angiogenesis
  • Clinical Practice/Patient Care
  • Clinical and Rehabilitative Aspects of Osteoarthritis
  • Cytokines, Mediators, and Gene Regulation
  • Cytokines, Mediators, and Gene Regulation I
  • Cytokines, Mediators, and Gene Regulation II
  • Education/Community Programs
  • Epidemiology and Health Services Research I: Epidemiology and Outcomes in Rheumatic Disease
  • Epidemiology and Health Services Research II: Epidemiologic Risk Factors in the Development of Rheumatic Disease
  • Epidemiology and Health Services Research III: Rheumatic Diseases and Cardiovascular Disease and Risk Assessment
  • Epidemiology and Health Services Research IV: Outcomes and Costs in Rheumatic Disease
  • Epidemiology and Health Services Research V: Rheumatoid Arthritis Management in the Treat-to-Target Era
  • Epidemiology and Health Services Research: Epidemiology and Outcomes of Rheumatic Disease I
  • Epidemiology and Health Services Research: Epidemiology and Outcomes of Rheumatic Disease II
  • Epidemiology and Health Services Research: Rheumatic Disease Pharmacoepidemiology
  • Epidemiology and Public Health
  • Factors Associated with Rheumatoid Arthritis
  • Fibromyalgia and Soft Tissue Disorders
  • Fibromyalgia and Soft Tissue Disorders I
  • Fibromyalgia and Soft Tissue Disorders II
  • Foot and Gait Disorders
  • Genetics and Genomics of Rheumatic Diseases
  • Imaging of Rheumatic Diseases I: Ultrasound and X-ray
  • Imaging of Rheumatic Diseases II: Magnetic Resonance Imaging
  • Imaging of Rheumatic Diseases III: Computed Tomography
  • Imaging of Rheumatic Diseases: Magnetic Resonance Imaging, Computed Tomography and X-ray
  • Imaging of Rheumatic Diseases: Ultrasound, Nuclear Medicine and Fluorescence Imaging
  • Infection-related Rheumatic Disease
  • Innate Immunity and Rheumatic Disease
  • Medical Education
  • Metabolic and Crystal Arthropathies
  • Metabolic and Crystal Arthropathies: Basic Science
  • Metabolic and Crystal Arthropathies: Clinical
  • Miscellaneous Rheumatic and Inflammatory Diseases
  • Miscellaneous Rheumatic and Inflammatory Diseases: Periodic Fever Syndromes
  • Miscellaneous Rheumatic and Inflammatory I
  • Muscle Biology, Myositis and Myopathies: Classification, Treatment and Outcome in Idiopathic Inflammatory Myopathies
  • Muscle Biology, Myositis and Myopathies: Clinical and Therapuetic Aspects of Idiopathic Inflammatory Myopathies
  • Muscle Biology, Myositis and Myopathies: Genetics, Autoantibodies and other Molecular Aspects of Idiopathic Inflammatory Myopathies and Models
  • Muscle Biology, Myositis and Myopathies: Pathogenesis in Idiopathic Inflammatory Myopathies
  • Orthopedics, Low Back Pain, and Rehabilitation
  • Osteoarthritis
  • Osteoarthritis - Clinical Aspects
  • Osteoarthritis - Clinical Aspects I: Weight, Activity, and Metabolic Effects on Osteoarthritis
  • Osteoarthritis - Clinical Aspects II: Structural Risks for Osteoarthritis End-points and Potential Treatments
  • Osteoporosis and Metabolic Bone Disease
  • Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis
  • Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic Diseases
  • Pediatric Rheumatology - Clinical and Therapeutic Aspects: Pediatric Systemic Lupus Erythematosus, Pediatric Vasculitis and Pediatric Myositis
  • Pediatric Rheumatology - Pathogenesis and Genetics
  • Pediatric Rheumatology: Clinical and Therapeutic Disease I: Juvenile Idiopathic Arthritis I
  • Pediatric Rheumatology: Clinical and Therapeutic Disease II: Juvenile Idiopathic Arthritis II
  • Pediatric Rheumatology: Clinical and Therapeutic Disease III: Childhood Systemic Lupus Erythematosus and Other Vasculidities
  • Pediatric Rheumatology: Clinical and Therapeutic Disease IV: Childhood Therapeutics and Response
  • Pediatrics
  • Pediatrics: Disease Flares
  • Physical/Occupational Therapy and Exercise in Patients with Rhematologic Disease
  • Plenary Session I: Discovery 2012
  • Plenary Session II: Discovery 2012
  • Plenary Session III: Discovery 2012
  • Programs and Literacy in Patients with Rheumatologic Diseases
  • Psychological Aspects of Rheumatologic Disease
  • Psychology/Social Sciences
  • Quality Measures and Innovations in Practice Management and Care Delivery
  • Rehabilitation Sciences
  • Rheumamtoid Arthritis - Human Etiology and Pathogenesis
  • Rheumatoid Arthritis - Clinical Aspects I: Drug Studies/Drug Safety/Drug Utilization/Disease Activity & Remission
  • Rheumatoid Arthritis - Clinical Aspects I: Risk Factors and Prediction of Rheumatoid Arthritis
  • Rheumatoid Arthritis - Clinical Aspects II: Clinical Features & Comorbidity/Cardiovascular Disease
  • Rheumatoid Arthritis - Clinical Aspects II: Long-term Outcome of Rheumatoid Arthritis, Observational Studies
  • Rheumatoid Arthritis - Clinical Aspects III: Infections/Risk Factors for Incident Rheumatoid Arthritis/Metrology/Classification/Biomarkers/Predictors of Rheumatolid Arthritis Activity & Severity
  • Rheumatoid Arthritis - Clinical Aspects III: Rheumatoid Arthritis and Cardiovascular Disease
  • Rheumatoid Arthritis - Clinical Aspects IV: Non-biologic Drugs for Rheumatoid Arthritis: New Insights on Comorbidities and Adverse Events
  • Rheumatoid Arthritis - Clinical Aspects V: Comorbidities in Rheumatoid Arthritis
  • Rheumatoid Arthritis - Clinical Aspects VI: Remission and Flare in Rheumatoid Arthritis
  • Rheumatoid Arthritis - Clinical Aspects VII: Prediction of Outcome in Rheumatoid Arthritis
  • Rheumatoid Arthritis - Human Etiology and Pathogenesis I: Early Pathogenesis of Rheumatoid Arthritis
  • Rheumatoid Arthritis - Human Etiology and Pathogenesis II: Cellular Effectors of Rheumatoid Arthritis and Novel Rheumatoid Arthritis Genome-Wide Association Studies
  • Rheumatoid Arthritis - Human Etiology and Pathogenisis
  • Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy
  • Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Comparative Efficacy and Novel Treatment Strategies in Rheumatoid Arthritis
  • Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy and Safety of Novel Entities
  • Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy of Approved Biologics
  • Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety & Efficacy of Janus Activated-Kinase (JAK) Inhibitors
  • Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety I
  • Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety II
  • Rheumatoid Arthritis: Animal Models
  • Sjögren's Syndrome - Clinical
  • Sjögren's Syndrome - Pathogenesis
  • Sjögren's Syndrome I - Pathogenesis
  • Sjögren's Syndrome II - Clinical
  • Spondylarthritis and Psoriatic Arthritis - Pathogenesis, Etiology
  • Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Psoriatic Arthritis
  • Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Psoriatic Arthritis and Spondyloarthritis
  • Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Spondyloarthritis I
  • Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Spondyloarthritis II
  • Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment
  • Spondyloarthritis and Psoriatic Arthritis - Pathogenesis, Etiology
  • Systemic Lupus Erythematosus
  • Systemic Lupus Erythematosus - Animal Models
  • Systemic Lupus Erythematosus - Clinical Aspects and Treatment I: Renal
  • Systemic Lupus Erythematosus - Clinical Aspects and Treatment II: Clinical Aspects/Pregnancy
  • Systemic Lupus Erythematosus - Clinical Aspects and Treatment III: Cardiovascular
  • Systemic Lupus Erythematosus - Clinical Aspects and Treatment IV: Therapeutics
  • Systemic Lupus Erythematosus - Clinical Aspects and Treatment V: Clinical Aspects
  • Systemic Lupus Erythematosus - Human Etiology and Pathogenesis
  • Systemic Lupus Erythematosus - Human Etiology and Pathogenesis I
  • Systemic Lupus Erythematosus - Human Etiology and Pathogenesis II
  • Systemic Lupus Erythematosus: Clinical Aspects
  • Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s – Pathogenesis, Animal Models and Genetics
  • Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s – Clinical Aspects and Therapeutics
  • Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s – Clinical Aspects and Therapeutics I
  • Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s – Clinical Aspects and Therapeutics II
  • Systemic Sclerosis, Vasculitis, Crohn's and Spondylarthropathies
  • T-cell Biology and Targets in Autoimmune Disease
  • Vasculitis
  • Vasculitis: Clinical Aspects
  • Vasculitis: Clinical Trials
  • Vasculitis: Pathogenesis
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology